Key Highlights

● Sales rose and adjusted EPS was flat

● Full-year guidance was raised

● Knee sales declined on execution and China

● Shares rose strongly at the close

Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a major orthopedic name in the medical technology segment of healthcare, reported third-quarter results that combined broad gains with one conspicuous shortfall. Net sales rose from the prior-year quarter both as reported and in constant currency, adjusted Diluted Earnings per Share were flat, and the Warsaw, Indiana, company raised its full-year guidance for Organic Sales growth and adjusted earnings. Knees, its largest product category, went the other way.

Chief Executive Ivan Tornos said in the release that the company was pleased with the quarter, describing a "broad-based performance" that gave management confidence to raise its organic constant-currency growth outlook. Investors appeared to agree. According to market data, the shares rose strongly at the close, a significant move for a large device maker. The same report captured the central tension in its analysis, observing that Diversification is offsetting the knee problem without solving it.

Knees: Execution, China and a Competitive Market

Knee sales fell in both the US and international markets. On the conference call, Tornos attributed the weakness to the consolidation of the China distributor network, the transition of the US sales force and a competitive US knee market. Excluding China, he said, global knees would have been flat. He described the vast majority of the shortfall as expected and said it is driven by commercial execution, rather than by a problem with end-market demand.

The sales transition, known internally as Project Optima, involves converting independent representatives to direct employees, along with new incentive plans and new leadership. Todd Becker, whom Tornos described as a former leading US distributor, was recently named to lead the effort. Tornos said it takes more than a year to see the benefits of such changes, and he called the third stage of the transition "the riskiest." That candor matters because it signals that the company itself sees execution risk continuing into next year.

China offers a clearer timetable. Tornos said the distributor headwind laps in January, while According to market data, the consolidation subtracted a noticeable amount from overall growth in the quarter. Pricing was also a modest headwind but stayed within the company's full-year range, according to remarks on the call from management, where Paul Stellato spoke as interim chief financial officer.

Hips Keep the Momentum Going

Hip sales delivered a healthy gain, with growth in the US and faster constant-currency growth abroad. Management credited a triple-taper stem that has become the majority of its US hip stem sales, up from a smaller share in the prior quarter, along with the HAMMR impactor, which is now used in a sizeable minority of US primary hip procedures. OrthoGrid had its strongest quarter, with most of its sales coming from recurring revenue. In Japan, the launch of an iodine-coated stem and cup exceeded expectations, and management is increasing supply.

The hip performance gives the company a meaningful counterweight to knees, and it arrived at a time when one of its largest rivals was offering a less optimistic view. An October headline noted by Market commentary said Stryker (NYSE:SYK) had cut its outlook, citing factors including a hip and knee slowdown. Asked about market conditions, Tornos stopped short of agreeing that a market slowdown had arrived, and he characterized his company's knee performance mainly as an internal matter. Analysts also probed the subject directly, including questions about competitor commentary on procedure volumes.

S.E.T. and Technology Broaden the Base

The S.E.T. category, which spans sports medicine, biologics, foot and ankle, upper extremities, trauma, craniomaxillofacial and thoracic products, recorded solid growth on both a reported and a constant-currency basis. Management said franchises in the category grew at rates from mid-single digits to the high teens. Paragon, the foot and ankle Business acquired in April of last year, grew strongly, and management described it as a blueprint for future acquisitions. Trauma and restorative therapies declined, which management had expected.

The smallest reported category, which combines technology and data, bone cement and surgical products, grew the fastest. US technology and data sales climbed particularly quickly. Robotics, data and artificial intelligence solutions advanced at a strong rate, led by ROSA with OptimiZe and by TMINI, a cordless handheld system compatible with the Persona Knee. Zimmer Biomet extended its distribution agreement with THINK Surgical for that product, and the release also noted the launches of the Megalodon Dynamic Compression System and the SmartShot Marrow Access Device. Management said its plan to add robotic sales specialists remains on track.

Monogram's Timeline Moves Forward

Perhaps the most forward-looking news concerned Monogram, the autonomous robotics technology. Tornos said a premarket notification filing with US regulators is expected very soon, ahead of schedule, and that a surgeon-guided, fully autonomous version is now expected in the first half of next year, compared with a previous expectation of the following year. He was careful to point out that filing does not mean approval, a caveat echoed by market data, which said the launch could occur if clearance is obtained.

Tornos claimed advantages for the system in safety, speed, ease of use, reproducibility and accuracy, and he said there were no patient safety reports in the trial. Partial knee, hip and shoulder applications are planned. Analysts asked about the go-to-market plan, how surgeons would be approached and the long-term Market Share potential of the technology. None of those questions can be definitively answered until regulators act and surgeons gain experience with the system, so this remains a prospect rather than a contributor to current results.

Why Earnings Did Not Follow Sales Higher

The gap between sales growth and earnings deserves attention. GAAP diluted earnings per share declined at a double-digit rate. The company's reconciliation tables show that the prior-year quarter benefited from income linked to lower contingent consideration estimates, whereas the latest quarter included an expense for the same type of item. Selling, general and administrative costs also rose from the prior-year period, while restructuring and intangible amortization declined.

Adjusted earnings per share were unchanged even though adjusted net earnings fell, because a lower diluted share count offset lower adjusted operating profit. Adjusted gross Margin slipped and adjusted Operating Margin narrowed from a year earlier. Management told analysts that the full-year adjusted gross margin is now expected to be better than previously anticipated, while the full-year adjusted operating margin is expected to decline by slightly more than half a percentage point. Operating expenses as a share of sales remained an area of analyst interest during the question session.

Cash flow was a brighter spot. Operating Cash Flow was solid and free cash flow rose from the prior-year quarter, with management guiding to full-year free cash flow growth in the high single digits to low double digits. Share repurchases continued, and the company reported substantial repurchases for the year to date. Net Debt rose from the end of last year, leaving it somewhat higher despite strong cash generation.

Geography and Currency

Geographic results were relatively balanced. US sales rose at a slightly faster rate than the reported international figure, while international sales on a constant-currency basis grew a little more quickly than the domestic business. Currency therefore acted as a modest drag on the reported international number. The gap between the reported and constant-currency totals was small for the group, but it influenced the guidance arithmetic, because the company lowered its assumed full-year currency benefit.

Within knees, the international decline was steeper than the US decline on a reported basis, while the constant-currency international decline was narrower than the reported one. Hips told the opposite story, with international growth outpacing the US. market data calculated that overall constant-currency growth would have been higher without the China consolidation, which supports management's framing of the distributor change as a temporary but real drag. Investors will be able to check that framing once the January anniversary passes and the comparison eases.

The year-to-date view reinforces these relative positions. Knees are almost flat for the year to date on a constant-currency basis and slightly positive as reported, showing that most of the weakness has emerged recently. Hips, S.E.T. and the technology category all show healthier cumulative growth, with S.E.T. flattered by the addition of Paragon, as its organic constant-currency rate is well below its reported rate.

Parsing the Guidance Change

The full-year guidance change had several components. The reported revenue range narrowed by lifting the low end, with the top unchanged, as the expected foreign exchange benefit shrank. The constant-currency and organic ranges moved up more visibly, with the organic range rising at both ends. The adjusted earnings per share range moved up modestly, with the lower end shifting more than the upper end. Earlier in the year, a German-language market news report said that the company had already raised its earnings forecast with first-quarter results, so this update continues an upward pattern, albeit in smaller steps.

US sales growth slowed from the second quarter, according to market data, and sales growth for the year to date looks stronger than for the latest quarter because the Paragon Acquisition contributed to earlier comparisons. Organic constant-currency growth for the year to date therefore offers a more telling indicator than the higher reported figure.

Tax, Shares and the Debt Load

Several smaller lines helped shape the bottom line. The effective tax rate fell from a year earlier, and the adjusted tax rate declined by a smaller amount. The most important support came from the share count, which fell materially from the prior-year quarter. Management said it is pursuing a substantial repurchase total for the full year, although third-quarter Buybacks were comparatively modest, which implies that a larger amount had already been completed earlier in the year.

The Balance Sheet is a Factor in how much further repurchases and acquisitions can go. A market data earnings summary noted that cash declined and current debt increased, while the release showed net debt rising from the start of the year. Travis Steed of Bank of America (NYSE:BAC) asked about Merger appetite and earnings Leverage next year, indicating analysts see Capital allocation as part of the story. Tornos's description of Paragon as a blueprint suggests that acquisitions remain under consideration, although no new transaction was disclosed in the release, and the company did not provide any detail on one.

Tariffs, a recurring topic across medical device makers, did not feature in the prepared transcript. The release mentions them only in its forward-looking risk language, without quantifying any effect on the quarter.

Next Year's Early Outline

Tornos told analysts he expects next year to be better than this one, citing the China anniversary, Monogram, a full year of the Paragon comparison and go-to-market gains. He also acknowledged that the balance of tailwinds and headwinds is hard to quantify, and detailed guidance, including any earnings leverage, will arrive early next year. Analysts sought clarity on the timing of a US knee recovery, how far the sales transition has been derisked and whether merger activity or Private Equity interest in orthopedics might shape the industry.

Policy was another topic. Management noted that a program known as CJR-X begins in January of the year after next, while analysts asked about policy effects on end markets and about ambulatory surgery center growth. The picture that emerged was of a company benefiting from breadth, with a stock reaction that suggested relief, yet still needing to prove that its most important product line can recover under a new commercial model.

Questions From the Analyst Line

The breadth of questions on the call offers a guide to the debate around the stock. Mathew Blackman of TD Cowen focused on whether hip and S.E.T. growth can last and how knees recover. Rick Wise of Stifel asked about market conditions and rivals' comments on procedures. Vijay Kumar of Evercore ISI asked why next year ought to improve on this one. Chris Pasquale of Barclays asked how far the sales transition has been derisked, and Richard Newitter of Truist asked when US knees might accelerate.

Others looked beyond the coming quarters. Matthew Taylor of Jefferies (NYSE:JEF) asked about Monogram's long-term share potential, Patrick Wood of UBS (NYSE:UBS) about go-to-market plans and surgeon messaging, and Caitlin Cronin of Canaccord Genuity about the THINK Surgical partnership. Larry Biegelsen of Wells Fargo (NYSE:WFC) brought up private equity interest in orthopedics, and Steve Lichtman of William Blair asked about Operating Expense levers. Together, these questions show that attention has moved from the raised guidance itself toward whether the commercial reorganization and robotics pipeline can sustain growth once easier comparisons have been absorbed.